Catal­ent snaps up Promether­a's cell ther­a­py sub­sidiary, com­plete with a Bel­gian plant to help scale plas­mid DNA ef­forts

Rid­ing a wave from its work on the Covid-19 re­sponse, CD­MO gi­ant Catal­ent has been ex­pand­ing rapid­ly in next-gen cell ther­a­pies as it gets prepped for a fu­ture boom. Af­ter a cou­ple of snap ex­pan­sions at its Bel­gian cam­pus, Catal­ent is now adding an­oth­er fa­cil­i­ty at the site as part of its plan to bol­ster its EU hub.

Catal­ent has ac­quired Promethera’s He­pat­ic Cell Ther­a­py Sup­port SA sub­sidiary and its 32,40-square-foot fa­cil­i­ty in Gos­selies, Bel­gium, part of the New Jer­sey drug­mak­er’s con­tin­ued ex­pan­sion plans in the coun­try, the com­pa­nies said Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER